Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | TGM2 | P21980 | 13/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | F13A1 | P00488 | 6/20 | 0.46 |
| ▸ | TGM1 | P22735 | 6/20 | 0.46 |
| ▸ | TGM6 | O95932 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14056368 | 0.89 | HTT (0.49) | HTTSMN1; SMN2TGM2LMNAMAPT | |
| SCHEMBL14057319 | 0.87 | TGM2 (0.59) | HTTSMN1; SMN2TGM2LMNAF13A1 | |
| SCHEMBL14057401 | 0.85 | TGM2 (0.55) | HTTSMN1; SMN2TGM2LMNAMAPT | |
| SCHEMBL14056390 | 0.85 | TGM2 (0.58) | HTTSMN1; SMN2TGM2LMNAF13A1 | |
| SCHEMBL14054873 | 0.85 | TGM2 (0.54) | HTTSMN1; SMN2TGM2LMNAMAPT | |
| SCHEMBL14057281 | 0.84 | TGM2 (0.49) | HTTSMN1; SMN2TGM2LMNAMAPT | |
| SCHEMBL14056382 | 0.84 | TGM2 (0.56) | HTTSMN1; SMN2TGM2LMNAMAPT | |
| SCHEMBL14055571 | 0.84 | HTT (0.46) | HTTSMN1; SMN2TGM2LMNAMAPT | |
| SCHEMBL14056225 | 0.83 | TGM2 (0.48) | HTTSMN1; SMN2TGM2LMNAMAPT | |
| SCHEMBL14053897 | 0.83 | TGM2 (0.51) | HTTSMN1; SMN2TGM2LMNAF13A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889716-B2 | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120302539-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2012-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302539-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HTT, TGM2, GRN | HTT 1/4885SMN1; SMN2 216/4885TGM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.